NAD recommends Nucleus Genomics modify embryo screening ad claims
Nucleus Genomics, a consumer genetics company offering preimplantation genetic screening, has been told by the National Advertising Division (NAD) to modify or discontinue a series of advertising claims for its Nucleus IVF+ embryo selection service. The NAD, which operates under BBB National Programs as a US industry self-regulatory body, identified multiple unsupported claims across a website slideshow and an Instagram video. Nucleus has said it will appeal.
The IVF+ service is marketed to individuals undergoing in vitro fertilisation, positioning genetic analysis as a tool to compare embryos produced by the same two biological parents. The disputed advertising showed a side-by-side embryo comparison chart assigning specific numerical values for cancer risk, type 2 diabetes risk, autism spectrum disorder risk, eye and hair colour, height in inches, and IQ points.
What NAD found unsupported
The NAD concluded that the slideshow's framing, moving from "guessing" to "clarity" as a doctor selects an embryo, created a misleading impression of predictive accuracy across several categories. On disease risk, the body accepted that Nucleus had supplied polygenic risk score data, but found the evidence did not demonstrate how accurately the tool could rank a full group of five embryos, or justify the percentage-point differences displayed for breast cancer, type 2 diabetes and autism spectrum disorder.
On physical traits, NAD found that presenting single definite values for eye and hair colour implied a level of predictive certainty that DNA-based colour models do not yet support. Similarly, presenting plus-or-minus inch estimates for height, and specific IQ-point differences in the chart, went beyond what the company's proprietary performance measures could validate. NAD additionally noted that founder statements in the Instagram video, asking whether a viewer would prefer a taller or smarter baby and referencing "the smartest" of six embryos, reinforced those implied claims.
During the inquiry, Nucleus voluntarily and permanently withdrew its broadest claim, that the service lets users "see your future child's health, traits, and potential before pregnancy even begins." NAD will treat this as a formal discontinuation.
Regulatory and market context
The ruling lands at a sensitive moment for polygenic embryo screening, a field that has attracted regulatory and bioethical scrutiny in several jurisdictions. Professional bodies including the American Society for Reproductive Medicine have previously cautioned against clinical use of polygenic scores for non-disease traits such as intelligence and height, citing the complexity of gene-environment interactions and the limited predictive power of current models at the individual level.
Nucleus is not the only company in this space. A small number of firms, primarily in the US, offer polygenic screening layered on top of standard preimplantation genetic testing for aneuploidy. The sector has grown alongside declining sequencing costs and increasing consumer familiarity with direct-to-consumer genetics, but it remains largely outside the purview of the FDA, which does not currently regulate laboratory-developed tests for embryo selection under the same pathway as medical devices. That regulatory gap has given companies significant latitude in how they advertise, making NAD inquiries one of the more active accountability mechanisms available to US consumers in this space.
Nucleus's decision to appeal means the case moves to the National Advertising Review Board, NAD's appellate body. The outcome will be watched by competitors and legal teams across the consumer genomics sector, given the breadth of the claims at issue and the growing commercial interest in trait-based embryo selection services.